Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 HA-DOTATATE in Somatostatin Receptor Positive Tumours
NCT03145857Phase 2Terminated
- Sponsor
- American Health Staffing Group
- Start
- Mar 2020
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-HA-DOTATATE in neuroendocrine tumors (NETs), sponsored by American Health Staffing Group. Primary endpoints: Change in vital signs after first [68]Ga-HA-DOTATATE injection, Changes in haematology and biochemistry after first [68]Ga-HA-DOTATATE injection and 3 more. Started Mar 2020; status: terminated.
02
Drugs
68Ga-HA-DOTATATE
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03145857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145857.